Ultime notizie per Nymox Pharmaceutical (OTC:NYMXF) Azioni

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

NYMOX PHARM CORP by Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp

TOP Ships Inc. (the "Company" or "TOP Ships") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOPS#NYSE">TOPS</a>), an international owner and operator of modern, fuel-efficient "ECO" tanker vessels, announced today that it intends to effect a spin-off of two of its Suezmax tanker vessels.
Rubico Inc. ("Rubico"), currently a subsidiary of TOP Ships, would become an independent publicly-traded company listed on the Nasdaq Capital Market as a result of the planned spin-off. The initial assets of Rubico will be the M/T Eco Malibu and M/T Eco West Coast, each a modern, high specification, scrubber-fitted and fuel-efficient 157,000 dwt Suezmax tanker.
As part of the spin-off transaction, TOP Ships intends to distribute 100% of the common shares of Rubico to its securityholders of record as of June 16, 2025. The distribution of common shares of Rubico is expected to be made on or around June 30, 2025. Following the spin-off, there are expected to be no overlapping board members or executive officers between Rubico and TOP Ships.
In the spin-off distribution, TOP Ships intends to distribute 100% of the common shares of Rubico pro rata to the common shareholders of TOP Ships and to all holders of outstanding common stock purchase warrants of TOP Ships on an as-exercised basis.

News

Dividends

TOPS

TOP Ships Announces Planned Spin-Off Of 2 Fuel-Efficient Suezmax Tankers Into Newly Public Nasdaq Company Rubico Inc., With Share Distribution To TOP Ships Securityholders Expected By June 30, 2025

MAMO

Massimo Group Announces Strategic Nearshoring Initiative To Transition To Nearshoring Manufacturing Model

Approximately 500 million redemptions are processed through GFT Rewards annually
Datavault AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>), a leader in AI-driven data experience, valuation and monetization, today announced a strategic licensing agreement with GFT Rewards to deploy ADIO&#xAE;-enabled, Web 3 mobile rewards across major distribution channels from airports and retail chains to movie exhibitors, college campuses and Ride-Hailing networks.
GFT Rewards is a pioneer in web 3 promotions and rewards, transforming how shoppers discover and redeem offers across mass diverse distribution channels from grocery stores, stadiums and movie theatres, to college campuses and Ride-Hailing Networks. By partnering with major brands like T-Mobile, Kroger, Toshiba, Marvel and others, GFT Rewards reinvented reward creation, distribution, redemption and reimbursements, making it frictionless and profitable for retailers to hyper-scale, target and personalize their rewards and loyalty platforms, while making it easier and much more abundant for consumers to engage and reap the benefits.
In its latest initiative, GFT Rewards has teamed up with Datavault AI and ADIO&#xAE; to set a new standard for programmatic reward distribution, from coupons and rebates to web 3, tokenized loyalty incentives. Leveraging ADIO's patented inaudible-tone technology, this collaboration enables retailers and brands to deliver cash-redeemable or tokenized loyalty offers directly to consumers' mobile devices. Under the terms of the agreement, Datavault AI will receive a fee for every reward redemption managed and redeemed through GFT's platform with ADIO.
Datavault AI has licensed its proprietary audio-based ADIO&#xAE; solution to GFT Rewards to trigger secure mobile reward redemptions through ultrasonic tones embedded in advertisements and digital media. These rewards are instantly redeemed at the point of sale, offering real-time incentives to shoppers. GFT Rewards will utilize its GFT Cash App to execute revenue-share payments to partners with AI analytics and redemption reporting built into its dashboard.
"Retailers are experiencing a growing demand for frictionless, instant savings and rewards tied to digital ads and proximity triggers," said Jonas Hudson, Co-CEO of GFT Rewards. "This partnership combines our financial infrastructure and marketplace with Datavault AI's ultra-targeted, tone-based ad delivery system to enable the next generation in Web 3 rewards, sales and ROI for brands, distributors and IP."
The global mobile coupon market continues its rapid ascent. Valued at $603.3 billion in 2023, the market is projected to reach $1.6 trillion by 2030, reflecting accelerating digital adoption and evolving shopping habits among global consumers. (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcapitaloneshopping.com%2Fresearch%2Fcoupon-statistics%2F&amp;esheet=54264966&amp;newsitemid=20250604125554&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcapitaloneshopping.com%2Fresearch%2Fcoupon-statistics%2F&amp;index=1&amp;md5=57e9f23f9170ad202a617bf70ccfb08d">https://capitaloneshopping.com/research/coupon-statistics/</a>)
"These numbers show that while coupons are ubiquitous, their impact lies in how strategically they are delivered and redeemed," said Jonas Hudson, Co-CEO of GFT Rewards. "Brands that optimize their loyalty and incentive strategies—particularly via mobile—stand to gain significant consumer engagement and revenue lift."
As shoppers increasingly expect instant, low-friction experiences, retailers and brands are moving toward technologies that enable real-time engagement, automated delivery and seamless integration within everyday media. This shift is fueling demand for promotions that can be activated passively, in the moment and in response to media exposure—precisely the type of delivery model ADIO&#xAE; supports.
Unlike legacy solutions reliant on barcodes or QR codes, ADIO&#xAE; operates via encrypted, high-frequency tones that can be layered into any audio environment—streaming services, television broadcasts, retail PA systems or social video. The technology enables fully passive activation, with coupons appearing as notifications or digital wallet entries the moment the tone is detected.
"By integrating ADIO&#xAE; technology into the cash ecosystem of GFT, we're giving advertisers a way to turn impressions into transactions instantly," said Nathaniel Bradley, CEO of Datavault AI. "ADIO&#xAE; is an ideal solution for this kind of performance marketing, and we expect significant velocity in adoption as retailers and brands look to reduce friction in the promotional funnel. GFT's system is already rolling out across select banners with national reach, and we anticipate this model becoming a standard for performance-based in-store media."
The agreement expands Datavault AI's channel access in key sectors, including consumer packaged goods (CPG), fast-moving consumer goods (FMCG) and high-volume grocery retail, all of which are facing increased pressure to demonstrate ROI on every promotional dollar. The ADIO&#xAE; + GFT Rewards software delivers SKU-level tracking, geo-anchored performance reporting and immediate economic attribution, creating a new standard for coupon campaign accountability.

Contracts

DVLT

Datavault AI Enters Strategic Licensing Agreement With GFT Rewards To Deploy ADIO-Enabled, Web 3 Mobile Rewards Across Major Distribution Channels

Citigroup analyst Xiaopo Wei initiates coverage on Chagee Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHA#NASDAQ">CHA</a>) with a Buy rating and announces Price Target of $43.7.

Price Target

Initiation

Analyst Ratings

Citigroup Initiates Coverage On Chagee Holdings with Buy Rating, Announces Price Target of $43.7

BKTI

BK Technologies To Join Russell 2000 And Russell 3000 Indexes

Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) ("Nixxy" or the "Company"), an AI-powered data and communications infrastructure company, today announced the successful acquisition of the Leadnova.ai platform assets from the NexGenAI suite of companies. Nixxy also reported that it generated approximately $5.2 million in unaudited gross revenue for the month of May 2025 up from approximately $1.4 million in April 2025.

NIXX

Nixxy Acquires Leadnova.ai Platform Assets From NexGenAI Suite Of Companies; Nixxy Generates Gross Revenues Of About $5.2M In May 2025

GlobalFoundries Announces $16B Investment To Reshore Essential Chip Manufacturing And Accelerate AI Growth

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D").
The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.

Biotech

General

BDRX

Biodexa Pharmaceuticals Announces First Patient Dosed In Phase 2 Investigator-Initiated Trial Of Tolimidone For Type 1 Diabetes At University Of Alberta, Evaluating Insulin And Glucose Markers Across Three Dose Groups with Potential For Study Expansion

Dollar Tree Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)&nbsp;stock is <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower during the premarket</a>&nbsp;after its first-quarter 2025 earnings report.
Net sales increased 11.3% to $4.6 billion, beating the consensus of $4.53 billion and the management guidance of $4.5 billion—$4.6 billion.
Same-store net sales increased 5.4%, driven by a 2.5% increase in traffic and a 2.8% <a target="_blank" href="https://www.benzinga.com/trading-ideas/previews/25/06/45754249/dollar-tree-q1-earnings-preview-can-the-discount-retailer-beat-and-raise-like-peer-dollar-general" rel="noreferrer noopener">increase in average ticket</a>, beating the management guidance growth of 3% – 5%.
6.4% consumables <a target="_blank" href="https://corporate.dollartree.com/_assets/_fb720ee9222d1724ca4693e29c9ff376/dollartreeinfo/db/857/11067/pdf/Dollar+Tree+Inc.+Q1+2025+IR+Supplemental+-+FINAL+AS+PUBLISHED.pdf" rel="noreferrer noopener">comp</a> and 4.6% discretionary comp – highest discretionary comp growth since Q4 2022.
On Wednesday, Dollar Tree reported adjusted earnings of $1.26 per share, beating the analyst estimate of $1.21, better than management expectation of $1.10 – $1.25.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44677660/the-new-bull-case-for-dollar-tree-raise-prices-boost-margins-blame-tariffs" rel="noreferrer noopener">Dollar Tree Surges Nearly 8% After Citi Upgrade: Analysts Say Tariffs Could Boost Margins, Not Hurt Them</a>
Gross profit increased 11.7% to $1.6 billion. The gross margin expanded 20 basis points to 35.6%, driven primarily by lower freight, improved mark-on, and lower occupancy costs due to sales leverage, partially offset by increased distribution, <a href="https://www.benzinga.com/pressreleases/25/06/b45766244/dollar-tree-inc-reports-results-for-the-first-quarter-fiscal-2025">shrink, and markdown costs</a>.
Adjusted operating income increased 1.4% to $387.8 million, and adjusted operating margin contracted 80 basis points to 8.4%.
In March, the company <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44491397/dollar-tree-q4-earnings-surpass-estimates-unloads-family-dollar-for-1b" rel="noreferrer noopener">agreed to sell</a> the Family Dollar business to Brigade and Macellum for $1.007 billion. Net proceeds are estimated to total approximately $800 million. Additionally, Dollar Tree expects the economic impact of tax benefits from losses on the sale to be approximately $350 million. The deal is expected to close in the second quarter of fiscal 2025.
Fiscal Outlook
Dollar Tree reaffirms <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44491397/dollar-tree-q4-earnings-surpass-estimates-unloads-family-dollar-for-1b" rel="noreferrer noopener">fiscal year 2025 sales&nbsp;guidance</a> of $18.5 billion—$19.11 billion versus a consensus of $18.95 billion, based on comparable store net sales growth of 3% to 5%.
The company said its outlook assumes the current tariff level remains in effect for the balance of the fiscal year and that it will be able to mitigate most of the incremental margin pressure from higher tariffs and other input costs.
The company raised its adjusted earnings guidance from $5.00-$5.50 per share to $5.15-$5.65 per share compared to analysts estimate of $5.21.
As Dollar Tree will bear the full year of the costs to support Family Dollar but only expects to receive offsetting reimbursement income in the second half of the year, the company&#8217;s full-year earnings will be negatively impacted by approximately 30 cents to 35 cents per share, with that impact concentrated in the first two quarters of the fiscal year.
Second Quarter 2025 Outlook
Given trends and expectations for the balance of the quarter, Dollar Tree expects Q2 comparable net sales growth to be towards the higher end of its full-year outlook range of 3% to 5%.
Over the balance of fiscal 2025, the company expects to mitigate the earnings impact of the cost pressures it faces, including higher tariffs.
In the near term, it expects to see some earnings volatility based on the timing of the various inputs and outputs to the company&#8217;s financial results.
The company expects that the second-quarter adjusted EPS from continuing operations could be down as much as 45% to 50% year-over-year before re-accelerating in the third and fourth quarters to meet its full-year earnings outlook.
On Tuesday, the company&#8217;s rival Dollar General Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) stock closed around 16% higher at $112.57 after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45746307/dollar-general-boosts-annual-outlook-despite-ongoing-tariff-uncertainty" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
Dollar Tree updated its expectations for the year, primarily to reflect its outperformance in the first quarter and the tariff uncertainty. It now expects fiscal year 2025 sales growth of approximately 3.7% to 4.7%, compared to its previous expectation of approximately 3.4% to 4.4%.
Same-store sales growth is expected to be approximately 1.5% to 2.5%, compared to its previous expectation of approximately 1.2% to 2.2%
Price Action: DLTR shares traded higher by 3.10% at $69.22 in premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?</a></li>
</ul>

Earnings

Retail Sales

Movers

Trading Ideas

DLTR

Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs

Citigroup analyst David Lebowitz upgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raises the price target from $83 to $129.

Upgrades

BPMC

Citigroup Upgrades Blueprint Medicines to Neutral, Raises Price Target to $129

<ul>
<li>Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market</li>
<li>Evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development</li>
<li>Cost-efficient approach&nbsp;enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value</li>
<li>Synergistic combination therapies&nbsp;under evaluation could redefine treatment standards in veterinary and human applications</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit" or the "Company") today announced that it has entered into a joint development agreement with Manoira Corporation ("Manoira"), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Conduit's AZD1656 and AZD5658, both clinical-stage glucokinase activators, in animal health indications, providing Conduit with high-value translational data across human and veterinary applications.
Manoira will focus its initial evaluation of AZD1656 in animal osteoarthritis, a common degenerative joint condition in companion animals, to generate preclinical data that will better inform Conduit's human clinical programs. Notably, early animal studies conducted by AstraZeneca suggest that glucokinase activators may have therapeutic potential in osteoarthritis1. In addition, Manoira plans to evaluate a novel combination of its patented CBDA co-crystal with AZD1656 and AZD5658 for the treatment for osteoarthritis in animals.
This cost-efficient collaboration allows Conduit to accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining 100% ownership of all data and intellectual property generated relating to AZD1656 and AZD5658 for human applications. The partnership not only enhances Conduit's core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary market, creating a dual-track value proposition for its shareholders. The parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed as a result of any such findings. Additionally, Manoira will evaluate AZD5658 for veterinary applications, expanding the utility of Conduit's glucokinase activator portfolio and supporting cross-species insight generation.

Conduit Pharmaceuticals And Manoira Announce Strategic Joint Development Agreement To Evaluate Glucokinase Activators AZD1656 And AZD5658 For Veterinary Use

LIPO

Lipella Pharmaceuticals Re-Signs Manufacturing Collaboration Agreement With Cook MyoSite For LP-310 Clinical Development

Management

HNRG

Hallador Energy Company Appoints Todd Telesz As CFO

PAX's award-winning portable dry herb cannabis vaporizers now more broadly available through Greenlane's distribution platform

GNLN

Greenlane Renews Distribution Agreement With PAX

Gadolinium-160 is a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapies. &nbsp;
- Supply agreement is for four years' supply of enriched Gd-160, commencing in 2026, with an expected minimum contract value of $1 million per annum.
ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has recently entered into a supply agreement with Isotopia Molecular Imaging Ltd. related to the supply of enriched Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
This agreement addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumours, and other malignancies.
Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The supply agreement is for four years' supply, commencing in 2026, with an expected minimum contract value of $1 million per annum.
The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years.
Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms."
Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US."
Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumour-seeking molecules.
It is expected that Gd-160 will be enriched using the Company's Quantum Enrichment process, a novel laser-based approach to enriching isotopes. The Gd-160 plant will be part of a large Quantum plant that the Company is in the process of designing and constructing. Additional isotopes that are expected to be enriched in this large-scale laser facility include Nickel-64, Zinc-68, Ytterbium-176, Barium-137, Ytterbium-171 and Lithium 6/7.
This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. The Company is in discussions with other customers who require Gd-160 and expects to sign additional orders during 2025

ASPI

ASP Isotopes And Isotopia Enters Supply Agreement For Gadolinium-160 To Help Accelerate Terbium-161 Production For Advanced Cancer Therapies With Expected Minimum Contract Value Of $1M Per Year

PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), owner of brands such as Tommy Hilfiger and Calvin Klein, will release earnings results for the first quarter, after the closing<a href="https://www.benzinga.com/quote/PVH/earnings"> bell on Wednesday, June 4</a>.
Analysts expect the New York-based company to report quarterly earnings at $2.25 per share, down from $2.45 per share in the year-ago period. PVH projects to report quarterly revenue at $1.93 billion, compared to $1.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 30, Needham analyst Tom Nikic initiated coverage on PVH with a Buy rating. He gave the company a price target of $115.
With the recent buzz around PVH, some investors may be eyeing potential gains from the company's dividends too. Currently, PVH offers an annual dividend yield of 0.18%. That&#8217;s a quarterly dividend amount of 4 cents per share (15 cents a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $3,301,600 or around 40,000 shares. For a more modest $100 per month or $1,200 per year, you would need $660,320 or around 8,000 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.15 in this case). So, $6,000 / $0.15 = 40,000 ($500 per month), and $1,200 / $0.15 = 8,000 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
PVH Price Action: Shares of PVH gained 0.5% to close at $82.54 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Fell</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From PVH Stock Ahead Of Q1 Earnings

Citigroup analyst Ryan Levine downgrades Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) from Buy to Neutral and raises the price target from $232 to $318.

Downgrades

Citigroup Downgrades Constellation Energy to Neutral, Raises Price Target to $318

Legal

SGBX

Safe and Green Holdings Receives Court-Ordered Award Of More Than $1.1M For Attorney's Fees And Costs Part Of EDI Litigation

Editor&#8217;s note: This story was corrected to update the earnings estimates.
Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/b45757637/asana-announces-first-quarter-fiscal-2026-results">details from the report.&nbsp;</a>
The Details: Asana reported quarterly earnings of five cents per share, which beat the Street estimate of two cents. Quarterly revenue of $187.27 million exceeded the consensus estimate of $185.4 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
For the first quarter of fiscal 2026, Asana reported: 
<ul class="wp-block-list">
<li>The number of Core customers, or customers spending $5,000 or more on an annualized basis, grew to 24,297, an increase of 10% year-over-year. Revenues from Core customers grew 10% year-over-year.</li>
<li>The number of customers spending $100,000 or more on an annualized basis grew to 728, an increase of 20%.</li>
<li>Overall dollar-based net retention rate was 95%.</li>
</ul>
&#8220;Just months after launching AI Studio, we&#8217;ve already crossed $1 million in ARR and head into Q2 with a robust, rapidly growing global pipeline,&#8221; said Dustin Moskovitz, CEO of Asana. 
&#8220;With new offerings like the AI Studio Plus package, and Smart Workflow Gallery, we&#8217;re making these transformative AI capabilities even more accessible,&#8221; Moskovitz added. 
Outlook:&nbsp;Asana sees second-quarter adjusted earnings of four cents to five cents per share, versus the four cent estimate, and revenue in a range of $192 million to $194 million, versus the&nbsp;$192.19 million&nbsp;analyst estimate.
Asana raised its fiscal 2026 adjusted EPS guidance from a range of 19 cents to 20 cents to 22 cents, versus the 33 cent estimate, and widened its revenue outlook from a range of $782 million to $790 million&nbsp;to&nbsp;a new range of $775 million to $790 million, versus the&nbsp;$857.76 million&nbsp;estimate.
ASAN Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Asana stock was down 12% at $16.69 in Wednesday's premarket trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Tech

ASAN

Asana Reports Q1 Earnings: Earnings, Revenues Beat (CORRECTED)

Citigroup analyst Marta Romero reinstates Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) with a Buy.

Comments

Nymox Pharmaceutical

Notizie

Ultime notizie per Nymox Pharmaceutical (OTC:NYMXF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO